湖南景峰医药股份有限公司 2021 年第三季度报告 证券代码：000908 证券简称：景峰医药 公告编号：2021-091 湖南景峰医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 246,227,086.57 | -33.75% | 559,766,301.67 | -40.2 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 313,539,215.10, a decrease of 44.49% compared to CNY 564,828,675.97 in the same period last year[20]. - The net profit attributable to shareholders was CNY 83,787,020.29, down 39.53% from CNY 138,553,429.36 year-on-year[20]. - The basic earnings per share decreased by 39.56% to CNY 0.0952 from CNY 0.1575 in the same period last year[20]. - The operating profit for the same period was 93.81 million yuan, down 41.98% year-on-year, while the net profit attributable to shareholders was 83.79 million yuan, a decline of 39.53%[35]. - The total profit for the first half of 2021 was CNY 85,148,299.06, down from CNY 158,144,264.64 in the first half of 2020, representing a decline of 46.1%[147]. - The total comprehensive income for the first half of 2021 was CNY 85,467,774.20, compared to CNY 132,303,592.32 in the first half of 2020, a decrease of 35.4%[148]. - The company's revenue from the pharmaceutical sector was approximately ¥257.80 million, a decrease of 17.20% year-over-year, with a gross margin of 76.15%, which is an increase of 25.93% compared to the previous year[48]. Cash Flow and Investments - The net cash flow from operating activities increased by 216.93%, reaching CNY 42,056,342.62, compared to a negative cash flow of CNY -35,967,711.91 in the previous year[20]. - The company reported a significant increase in cash flow from operating activities, amounting to ¥42.06 million, compared to a negative cash flow of ¥35.97 million in the previous period[44]. - The total cash inflow from investment activities reached ¥152,181,080.00, while cash outflow was ¥11,269,951.02, resulting in a net cash flow of ¥140,911,128.98 from investment activities[154]. - The company reported a significant increase in cash received from the disposal of subsidiaries, amounting to ¥140,800,000.00 in the first half of 2021[158]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,513,364,634.40, a decrease of 6.57% from CNY 2,690,014,013.86 at the end of the previous year[20]. - The company's total liabilities as of June 30, 2021, amounted to CNY 1,811,659,943.03, a decrease of 11.7% from CNY 2,051,835,713.87 at the end of 2020[140]. - The company's cash and cash equivalents decreased to CNY 105.30 million, representing 4.19% of total assets, down from 7.10% at the end of the previous year[52]. - The company's short-term borrowings were ¥794.92 million, which is 31.63% of total assets, a decrease from 23.69% the previous year[52]. Research and Development - The company has established a product structure target aiming for a ratio of 70% chemical drugs, 20% biological drugs, and 10% traditional Chinese medicine[36]. - The company is focusing on high-barrier generic drugs and has developed a diverse R&D pipeline, including high-end formulations and innovative drug research[36]. - The company's R&D investment decreased by 78.78% to ¥22.12 million from ¥104.24 million, reflecting a strategic reduction in funding[44]. - The company has a clear R&D strategy with a rich pipeline, including products in cardiovascular, oncology, and pain management fields, with several products in various stages of approval[40]. Market and Sales Strategy - The company operates in the pharmaceutical manufacturing industry, with a focus on cardiovascular, oncology, orthopedic, women's and children's health, digestive system, anti-infection products, and medical devices[27]. - The sales strategy combines self-operated and outsourced models, focusing on academic marketing and expanding into third-party and OTC markets[31]. - The company is focusing on marketing to tiered hospitals while expanding into private hospitals and lower-tier medical markets, anticipating stable sales growth[39]. - The company achieved a hospital coverage of over 1,000 for its anti-tumor drugs, with total hospital coverage exceeding 10,000, and expects to double this number in the next five years[40]. Risk Management - The company has faced various risks, including macroeconomic and market risks, which may impact its business operations[5]. - The company is facing significant risks from policy changes in the pharmaceutical industry, which could impact production costs and profitability due to reforms in drug pricing and procurement[59]. - The fluctuation in raw material prices poses a risk to production costs, prompting the company to strengthen market monitoring and strategic reserves[61]. - The company is focused on mitigating R&D risks by implementing a structured project management approach and enhancing its organizational framework[64]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[74]. - The company achieved a COD discharge of 20 mg/L, well below the standard of ≤500 mg/L, indicating compliance[74]. - The company reported a pH level of 7.58 for wastewater discharge, within the acceptable range of 6-9[74]. - The company has maintained normal operations for all pollution control facilities across its subsidiaries[76]. Corporate Governance - The company has appointed new independent directors and a financial director as of January 26, 2021[69]. - The company did not engage in any related party transactions during the reporting period[91]. - The company has not experienced any bankruptcy restructuring matters[88]. - The half-year financial report has not been audited[86]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 100,908[117]. - The largest shareholder, Ye Xiangwu, holds 15.01% of the shares, totaling 132,075,772 shares, with a decrease of 29,054,210 shares during the reporting period[118]. - The company did not implement any share buyback during the reporting period[113]. - The total number of shares held by directors and senior management is 133,241,710 shares after accounting for changes[120].

Business Performance - In 2020, Jingfeng Pharmaceutical achieved rapid business growth, capitalizing on opportunities in the Chinese pharmaceutical industry[5]. - The company's operating revenue for 2020 was ¥877,918,599.51, a decrease of 34.68% compared to ¥1,344,029,111.24 in 2019[22]. - The net profit attributable to shareholders was -¥969,922,381.52, representing a 7.88% decline from -¥882,806,468.65 in the previous year[22]. - The net cash flow from operating activities was -¥271,684,172.70, a significant drop of 851.12% compared to ¥36,170,428.51 in 2019[22]. - The total assets at the end of 2020 were ¥2,690,276,316.02, down 38.16% from ¥4,350,072,904.84 at the end of 2019[23]. - The net assets attributable to shareholders decreased by 72.08% to ¥442,774,825.95 from ¥1,585,604,781.55 in 2019[23]. - The company reported a basic earnings per share of -¥1.10, a 10% decrease from -¥1.00 in 2019[22]. - The company achieved a total revenue of 24,857.3 billion CNY in 2020, representing a year-on-year growth of 4.5%, which is 3.7 percentage points higher than the overall growth of large-scale industrial enterprises in the same period[37]. - The total profit reached 3,506.7 billion CNY, with a year-on-year increase of 12.8%, surpassing the average growth of 8.7% for large-scale industrial enterprises[37]. Research and Development - The company plans to focus on the development of high-barrier generic drugs and a multi-dimensional R&D production pipeline[5]. - The company emphasizes the importance of pharmaceutical innovation and core technology breakthroughs for future growth[5]. - The company has a product pipeline that includes unique offerings in cardiovascular, oncology, orthopedic, pediatric, digestive, and infection fields[31]. - The company emphasizes a research and development model that combines self-research and joint development, aiming for rapid breakthroughs in key areas[35]. - The company has established a stable internal and external research and development ecosystem through collaborations with universities and research institutions[35]. - The company is advancing the R&D of multiple international projects, including JS01, JS06, JS07, and others, with a focus on high-barrier generic drugs and innovative drug pipelines[54]. - The company has completed the II phase clinical trial for Fluorobiphenyl Ester Injection and is preparing for the III phase clinical trial[50]. - The company has a rich pipeline of products under research, including medical-grade hyaluronic acid gel and a new drug for cross-linked hyaluronic acid injection, with ongoing clinical trials[49]. - The company has established a research center to develop high-end formulations such as liposomes and nano-emulsions, enhancing its R&D capabilities[44]. - The company is actively conducting clinical research for its new drug projects, including JZB28 and JZB34, which are in the clinical research phase[64]. Financial Management - The company will not distribute cash dividends or bonus shares for the year[10]. - The audit report for the financial year was issued by Lixin Accounting Firm, confirming the accuracy of the financial statements[9]. - The company has maintained its main business without any changes since its listing[20]. - The company is actively improving its human resources management system to adapt to changes in the pharmaceutical industry[51]. - The company is focusing on integrating resources and optimizing asset allocation to enhance overall competitiveness[55]. - The company reported a significant increase in investment income of ¥330,760,362.07, accounting for 146.71% of total profit, primarily from the disposal of long-term equity investments[88]. - The company’s cash and cash equivalents decreased by 130.43% to -¥245,710,111.76 in 2020, reflecting the cumulative impact of reduced operating income and increased debt repayments[85]. - The company has received production administrative licenses for medical sodium hyaluronate gel (ophthalmology) and is steadily producing sodium hyaluronate series products[56]. - The company is preparing for the submission of supplementary application materials for several products, including Sodium Chloride Injection and Irinotecan Hydrochloride Injection[63]. Market Strategy - The company plans to increase its self-operated sales ratio to over 90% in the next five years, focusing on building a comprehensive sales network[34]. - The company is actively exploring the use of new media and e-commerce technologies for market expansion[34]. - The company is enhancing its marketing network and professional academic promotion to deepen market penetration[56]. - The company is committed to a multi-channel sales network, increasing its academic marketing efforts to enhance clinical influence[58]. - The marketing strategy focuses on professional self-operation as the main approach, supplemented by outsourcing and agency, aiming for deep marketing and market penetration[110]. Challenges and Risks - The company’s operational performance is subject to various risks, including macroeconomic and market risks[9]. - The company faced significant challenges due to the pandemic but continued to focus on foundational stability and steady development throughout 2020[32]. - The pharmaceutical manufacturing industry faced an average growth rate of approximately -11.2% in 2020 due to the pandemic, highlighting the challenges in the sector[37]. - The company is closely monitoring the impact of the COVID-19 pandemic on the pharmaceutical industry and adjusting strategies accordingly[118]. - The company is aware of potential tax policy changes that could increase tax burdens and is preparing to adapt to these changes[117]. Corporate Governance and Social Responsibility - The company has established a governance structure to protect the rights of shareholders and creditors, ensuring compliance with legal obligations[157]. - The company actively promotes employee rights and development, providing a platform for self-actualization and maintaining a harmonious corporate culture[158]. - The company emphasizes environmental responsibility, implementing measures for energy conservation and pollution reduction[159]. - The company engaged in charitable donations, including support for agricultural projects in Yunnan[160]. - The company is committed to poverty alleviation efforts, aligning its development with national strategies to support impoverished areas[161]. - In 2020, the company contributed a total of 5 million yuan to poverty alleviation efforts, focusing on targeted assistance to impoverished households[163]. Shareholder Information - The total number of shareholders at the end of the reporting period was 60,901, a decrease from 64,887 at the previous month-end[187]. - The largest shareholder, Ye Xiangwu, held 18.31% of the shares, with a reduction of 13,036,200 shares during the period[187]. - The company has not issued any new shares or conducted any share buybacks during the reporting period[186]. - The actual controller, Ye Xiangwu, remains unchanged and holds a significant influence over the company[190]. - The company has not reported any changes in major shareholders during the reporting period[189].

Financial Performance - The company's operating revenue for Q1 2021 was ¥120,869,292.97, a decrease of 60.73% compared to ¥307,774,671.77 in the same period last year[9] - Net profit attributable to shareholders was ¥27,546,229.31, representing a significant increase of 1,894.28% from ¥1,381,264.66 year-on-year[9] - Basic earnings per share rose to ¥0.0313, up 1,856.25% from ¥0.0016 in the same period last year[9] - The total operating costs for Q1 2021 were CNY 188.59 million, a decrease from CNY 309.47 million in the same period last year, representing a reduction of approximately 39%[41] - The net profit for Q1 2021 was CNY 19.20 million, compared to a net loss of CNY 7.44 million in Q1 2020, indicating a significant turnaround[42] - The total profit for Q1 2021 was CNY 21.50 million, compared to a total loss of CNY 2.53 million in Q1 2020, marking a significant improvement[42] - The operating profit for Q1 2021 was CNY 24.80 million, a recovery from an operating loss of CNY 1.66 million in the previous year[42] Cash Flow - The net cash flow from operating activities was ¥122,196,127.27, a decline of 249.25% compared to -¥81,875,651.10 in the previous year[9] - Cash and cash equivalents decreased by 39.73% to ¥98,952,894.06 from ¥164,196,069.51 due to repayment of maturing debts[16] - The total cash inflow from operating activities was CNY 296,548,898.02, an increase of 17.2% compared to CNY 253,053,256.10 in the previous period[50] - The net cash flow from operating activities was CNY 122,196,127.27, a significant recovery from a negative CNY 81,875,651.10 in the previous period[50] - Cash inflow from investment activities totaled CNY 83,318,080.00, compared to CNY 90,157,857.95 in the previous period[50] - The net cash flow from investment activities was CNY 74,233,389.56, recovering from a negative CNY 43,465,996.76[50] - Cash inflow from financing activities was CNY 152,867,000.00, down 41.7% from CNY 262,350,000.00[51] - The net cash flow from financing activities was negative CNY 257,404,227.60, compared to a positive CNY 28,936,944.25 in the previous period[51] - The ending cash and cash equivalents balance was CNY 98,952,894.06, down from CNY 309,724,694.41 in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,601,147,745.90, down 3.31% from ¥2,690,276,316.02 at the end of the previous year[9] - Total liabilities due within one year increased by 399.12% to ¥476,203,488.07 from ¥95,408,325.32, mainly due to reclassification of bonds[16] - The company's total liabilities decreased from CNY 2,051,835,713.87 to CNY 1,960,961,144.59, a decrease of approximately 4.4%[34] - Current liabilities increased from CNY 1,470,982,182.54 to CNY 1,778,937,711.89, an increase of approximately 20.9%[34] - Non-current liabilities decreased significantly from CNY 580,853,531.33 to CNY 182,023,432.70, a decline of about 68.7%[34] - The total equity attributable to shareholders increased from CNY 442,774,825.95 to CNY 473,658,413.37, an increase of about 6.9%[35] Research and Development - Research and development expenses decreased by 66.52% to ¥8,692,269.11 from ¥25,959,419.27, indicating reduced investment in R&D[16] - The cumulative investment in the new R&D center project reached ¥111,722,000 as of March 31, 2021[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 64,887[12] - The largest shareholder, Ye Xiangwu, holds 17.75% of the shares, amounting to 156,129,982 shares, with 120,847,486 shares pledged[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Other Financial Metrics - Non-recurring gains and losses totaled ¥89,853,928.15, with government subsidies contributing ¥7,189,937.94 and other non-operating income and expenses at -¥3,299,733.50[10] - Long-term equity investments decreased from CNY 146,761,012.77 to CNY 130,896,186.16, a decline of approximately 10.8%[33] - The company reported a tax expense of CNY 2.30 million for Q1 2021, down from CNY 4.90 million in the same period last year[42] - Other comprehensive income after tax for Q1 2021 was CNY 6.54 million, compared to a loss of CNY 0.12 million in Q1 2020[42] - The company recorded a credit impairment loss of CNY -0.32 million in Q1 2021, a significant improvement from a loss of CNY -9.84 million in Q1 2020[41] - The company has not undergone an audit for the first quarter report[56]

Financial Performance - Operating revenue for the reporting period was CNY 371,669,104.08, an increase of 8.09% year-on-year [7]. - Net profit attributable to shareholders was a loss of CNY 62,738,202.58, a decline of 69.54% compared to the same period last year [7]. - Basic earnings per share were CNY -0.0713, a decrease of 69.54% compared to the same period last year [7]. - The weighted average return on net assets was -3.71%, down from 4.76% in the previous year [7]. - The company reported a net profit attributable to shareholders of ¥75,815,226.78, a significant turnaround from a loss of ¥142,943,425.89 in the previous year, driven by investment income from Haimen Huiju [17]. - The net profit for the current period is ¥58,352,731.14, compared to a net loss of ¥164,490,818.74 in the previous period, showing a significant turnaround [52]. - The total comprehensive income for the current period is -74,175,754.03, compared to -216,600,460.65 in the previous period, reflecting a substantial reduction in losses [45]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 84,247,392.62, worsening by 15.08% year-on-year [7]. - Cash and cash equivalents decreased by 32.42% to ¥274,039,467.30 due to reduced sales collections impacted by the pandemic [15]. - Operating cash inflows decreased by 51.49% to ¥821,736,457.96, significantly affected by the pandemic's impact on sales collections [18]. - The net cash flow from operating activities turned negative at -¥120,215,104.53, a decrease of 372.23% compared to the previous year [18]. - Cash and cash equivalents at the end of the period totaled ¥269,608,211.84, down from ¥1,119,651,442.40 at the end of the previous period [59]. - The ending cash and cash equivalents balance was $1.74 million, down from $7.15 million, a decrease of approximately 75.6% [64]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,976,746,110.01, a decrease of 8.58% compared to the end of the previous year [6]. - Total liabilities decreased to ¥2,129,093,827.08 from ¥2,408,265,982.28, a reduction of about 11.6% [37]. - The company’s total assets amounted to ¥5,902,376,829.40, a slight increase from ¥5,871,464,300.47 [40]. - Total current assets amounted to 20,920,020.69 million, with cash and cash equivalents at 4,222,408.18 million and other receivables at 12,800,369.97 million [71]. - Non-current assets totaled 5,850,544,279.78 million, including long-term equity investments of 5,792,807,787.87 million and intangible assets of 33,176,017.68 million [72]. - Total liabilities reached 1,117,063,241.35 million, with current liabilities at 729,019,041.35 million and non-current liabilities at 388,044,200.00 million [73]. Shareholder Information - The total number of shareholders at the end of the reporting period was 65,793 [10]. - The largest shareholder, Ye Xiangwu, held 19.80% of the shares, with 130,624,636 shares pledged [11]. - The company did not engage in any repurchase transactions during the reporting period [12]. Investments and Strategic Initiatives - The company signed a strategic cooperation agreement with Changde Economic and Technological Development Zone for pharmaceutical R&D and manufacturing [20]. - The company plans to invest ¥282 million in the construction of an international pharmaceutical industry park in Changde [20]. - The company completed the transfer of 43.0086% equity in Haimen Huiju for ¥320 million, impacting its financial position [19]. - The company has invested CNY 10,964.71 million in the "Jingfeng Pharmaceutical New R&D Center Project" as of September 30, 2020, continuing to utilize raised funds for this project [25]. Operational Costs and Expenses - Total operating costs amounted to ¥397,081,206.26, with operating costs specifically at ¥85,762,215.25, down from ¥119,012,279.74, reflecting a decrease of about 28.0% [43]. - The company incurred sales expenses of ¥3,577,131.67, with management expenses totaling ¥43,939,396.83 [55]. - The research and development expenses for the current period amount to ¥95,141,086.83, slightly down from ¥101,370,815.27 in the previous period [50]. - The financial expenses for the current period are ¥84,289,517.94, an increase from ¥66,887,837.06 in the previous period [52]. Other Financial Metrics - Non-operating income included CNY 219,571,541.61 from the disposal of non-current assets [8]. - Investment income increased by 187.06% to ¥222,632,255.61, mainly due to the disposal of Haimen Huiju [16]. - The company reported an investment loss of ¥3,383,318.03, a significant decline from the previous period's investment income of ¥66,150,721.52 [55]. - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period [22]. - The company has no securities or derivative investments reported during the period [23][24].

证券代码：000908 证券简称：景峰医药 公告编号：2020-053 湖南景峰医药股份有限公司 关于参加湖南辖区上市公司 2020 年度投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公司 情况，湖南景峰医药股份有限公司（下称"公司"）将参加由中国证券监督管理委 员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合举办的 "湖南辖区上市公司 2020 年度投资者网上集体接待日"活动，现将有关事项公 告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式举行，投资者可以登陆"全景•路演天下"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动，活动时间为 2020 年 9 月 11 日（星期五）下午 15:00－17:00。 届时公司相关人员将与投资者进行在线沟通与交流，欢迎广大投资者积极参 与。 特此公告 湖南景峰医药股份有限公司董事会 2020 年 9 月 8 日 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥564,828,675.97, a decrease of 18.05% compared to ¥689,240,750.55 in the same period last year[18]. - The net profit attributable to shareholders of the listed company increased by 119.81% to ¥138,553,429.36, up from ¥63,034,487.58 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was -¥78,699,485.31, a decline of 239.27% compared to -¥23,196,914.38 in the same period last year[18]. - The net cash flow from operating activities was -¥35,967,711.91, a decrease of 125.09% from ¥143,363,742.00 in the previous year[18]. - Basic earnings per share increased by 119.97% to ¥0.1575, compared to ¥0.0716 in the same period last year[18]. - Total assets at the end of the reporting period were ¥4,056,630,719.44, a decrease of 6.75% from ¥4,350,072,904.84 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 8.41% to ¥1,721,505,745.01, compared to ¥1,588,007,410.82 at the end of the previous year[18]. - The company achieved operating revenue of 564.83 million yuan, a decrease of 18.05% compared to the same period last year[44]. - Operating profit reached 161.69 million yuan, an increase of 130.11% year-on-year[44]. - The company reported a significant increase in other receivables from CNY 42,320,783.44 to CNY 139,346,009.97, an increase of approximately 229.0%[182]. Research and Development - The company invested CNY 104.24 million in R&D, accounting for 18.45% of its revenue during the reporting period[51]. - The company holds a total of 190 patents, including 135 invention patents, with 12 new patents added[51]. - The company is committed to combining generic and innovative drug development, establishing a research center for advanced formulations like liposomes and nanoemulsions[32]. - The company is enhancing its R&D capabilities to accelerate new product launches and maintain competitiveness in the market[82]. - Research and development expenses were CNY 55,977,864.07, slightly up from CNY 54,752,920.35 in the previous year, indicating a growth of 2.22%[190]. Market and Product Development - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of chemical drugs, biological drugs, and traditional Chinese medicine, with over 20 GMP-certified production lines[26]. - The company has a diverse product pipeline, including cardiovascular products, anti-tumor products, orthopedic products, pediatric products, digestive system products, anti-infection products, and raw materials, with several products being unique in the national market[26]. - The company is focusing on the development of pediatric medications, with products like Children's Rejuvenation Granules aimed at treating common childhood ailments[31]. - The company has made significant progress in the generic drug sector, with key products in the digestive line being included in volume-based procurement in specific regions[31]. - The company is actively expanding its market presence in the cardiovascular drug sector, with the product "替罗非班" already listed in multiple provinces[45]. Financial Position and Investments - The company reported an investment income of ¥221,896,429.55, a significant increase of 209.14% from ¥71,778,635.33, primarily from the disposal of a subsidiary[60]. - The cash and cash equivalents decreased by 144.87% to -¥121,745,119.46, reflecting the overall financial strain during the period[60]. - Long-term equity investments increased to ¥447.58 million, representing 11.03% of total assets, due to the disposal of a 43.0086% stake in a subsidiary, which changed the influence from control to significant influence[69]. - The company has completed the construction of two 1000L biopharmaceutical production lines and is enhancing cooperation with several enterprises for joint development and contract manufacturing[33]. - The company has completed the production tasks based on market demand, ensuring stable supply of products and improving overall production efficiency[44]. Challenges and Risks - The COVID-19 pandemic has significantly impacted the pharmaceutical industry, leading to reduced hospital visits and lower medical consumption, which poses risks to the company's performance[91]. - The company faces risks from stringent pharmaceutical policies, which could affect production and profitability due to ongoing reforms in the healthcare system[81]. - Market competition is intensifying, with numerous domestic pharmaceutical companies leading to price volatility and increased pressure on profit margins[82]. - The company is implementing measures to mitigate raw material price fluctuations, including strategic reserves and independent development of key raw materials[83]. Corporate Governance and Compliance - The company has not engaged in any significant related party transactions during the reporting period[104]. - There are no major litigation or arbitration matters reported during the reporting period[99]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[109]. - The company has not implemented any employee incentive plans or stock ownership plans during the reporting period[103]. - The company has maintained a strong focus on environmental compliance, with all monitored pollutants meeting regulatory standards[122]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 68,966[145]. - Major shareholder Ye Xiangwu holds 19.80% of the shares, totaling 174,166,182 shares, with 43,541,546 shares pledged[145]. - The company has no foreign shareholding, with all shares held by domestic investors[143]. - The report indicates that there were no changes in the number of shares held by state-owned entities[145]. - The company reported a total of 38,804.42 million RMB in bond balance as of the reporting period[160].

Corporate Strategy and Vision - In 2019, the company reaffirmed its mission to "focus on quality pharmaceuticals and improve the quality of life," aiming to become a globally trusted professional pharmaceutical enterprise [3]. - The company plans to implement a strategy of "industrialization of generic drugs in line with international standards," emphasizing growth through reform and development [4]. - The company will enhance its marketing strategy by focusing on self-operated businesses while supplementing with agency outsourcing, aiming for a more refined and robust operation [4]. - The company aims for a self-operated sales ratio of over 90% in the next five years, focusing on direct sales while considering outsourcing only for rapid market coverage [31]. - The company is committed to maintaining a high-quality sustainable development path in line with international pharmaceutical industry trends [42]. Research and Development - In research and development, the company aims to accelerate its strategy of "short and long combination, nurturing the long with the short, and prioritizing speed," with increased R&D investment and improved project management [4]. - The company emphasizes a research and development model that combines self-research and joint development, focusing on key areas for rapid breakthroughs [32]. - The company is focusing on developing complex formulations and biopharmaceuticals to enhance future product competitiveness [66]. - The company has established long-term partnerships with dozens of pharmaceutical companies, providing customized R&D and production services for active pharmaceutical ingredients (APIs), with over 10 innovative drug projects in late clinical stages or awaiting approval [58]. - The company aims to launch 3-5 new products annually, focusing on key varieties included in the medical insurance directory [42]. Financial Performance - The company's operating revenue for 2019 was ¥1,344,029,111.24, a decrease of 48.02% compared to ¥2,585,696,901.89 in 2018 [20]. - The net profit attributable to shareholders for 2019 was -¥882,806,468.65, representing a decline of 572.56% from ¥186,812,660.38 in 2018 [20]. - The net cash flow from operating activities was ¥36,170,428.51, down 89.69% from ¥350,937,845.44 in the previous year [20]. - The total assets at the end of 2019 were ¥4,350,072,904.84, a decrease of 16.78% from ¥5,227,113,436.26 at the end of 2018 [20]. - The company reported a basic earnings per share of -¥1.0034 for 2019, compared to ¥0.2123 in 2018, a decline of 572.63% [20]. Market and Industry Trends - The pharmaceutical industry in China is undergoing significant reforms, with policies such as the "4+7" volume-based procurement impacting the market landscape [3]. - The total profit of the pharmaceutical manufacturing industry reached CNY 31.20 billion in 2019, with a year-on-year growth of 5.9% [33]. - The company is actively exploring the use of new media and e-commerce for market expansion [31]. - The domestic pharmaceutical market is highly competitive, with numerous manufacturers leading to price uncertainty; the company plans to enhance R&D capabilities and accelerate new product launches [128]. - Ongoing price reductions in drug procurement due to healthcare cost control measures may affect the company's profit margins; the company aims to expand sales to offset these impacts [131]. Quality Management and Compliance - The company will fully implement a comprehensive quality management system based on cGMP to enhance production quality and employee technical skills [4]. - The company has established a comprehensive quality management system to ensure compliance with GMP standards throughout the production process [31]. - The company achieved FDA cGMP certification and is enhancing its quality management capabilities through training and the establishment of a skilled engineering team [65]. - New regulations and standards in drug quality control require the company to enhance its production processes and ensure compliance with GMP standards [130]. - The company is committed to maintaining environmental compliance and has achieved all discharge standards across its facilities [191]. Investment and Funding - The total amount of funds raised for investment projects is CNY 87,314.03 million, with a cumulative investment of CNY 62,900.15 million, representing an investment progress of 72.00% [109]. - The company plans to utilize raised funds to supplement working capital, with a total of CNY 4 billion temporarily used for this purpose [110]. - The company has approved the temporary use of idle raised funds amounting to CNY 1.4 billion for working capital, with a usage period not exceeding 12 months [111]. - The company has committed to not engage in high-risk investments or provide financial assistance to entities outside of its controlling subsidiaries during the use of idle funds [111]. - The company has successfully returned all previously used idle funds to the special account, including CNY 2 billion by December 13, 2019 [111]. Social Responsibility and Environmental Impact - The company actively fulfills social responsibilities, including donations for poverty alleviation, with specific contributions such as funding for relocation projects in Guizhou and scholarships to universities [183]. - The company has established a dedicated department to enhance its support for poverty-stricken areas, leveraging its industrial advantages and nationwide resources [184]. - The company emphasizes environmental responsibility by implementing energy-saving measures and promoting green procurement practices [182]. - The company has a robust internal communication system to protect employee rights and enhance overall employee satisfaction [181]. - The company has achieved compliance in emissions, with total nitrogen discharge at 9.6375 mg/L, well below the limit of 50 mg/L [192]. Challenges and Risks - The pharmaceutical industry is facing significant policy risks due to ongoing reforms in drug pricing and procurement, which may impact profitability and production costs [127]. - Changes in tax policies could increase the company's tax burden, particularly if tax incentives for high-tech enterprises are altered [134]. - The ongoing COVID-19 pandemic poses operational challenges, but the company has established an emergency management team to mitigate its impact on production and sales [134]. - The company is implementing strategic reserves and developing key raw materials to mitigate risks from raw material price fluctuations [129]. - The company is diversifying its product offerings and closely monitoring bidding situations to address risks associated with product non-bidding [131].

湖南景峰医药股份有限公司 2020 年第一季度报告全文 湖南景峰医药股份有限公司 2020 年第一季度报告 2020 年 04 月 1 湖南景峰医药股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人叶湘武、主管会计工作负责人丛树芬及会计机构负责人（会计 主管人员）于哲声明：保证季度报告中财务报表的真实、准确、完整。 公司因疫情影响无法在2020年4月15日前披露2020年第一季度业绩预告， 根据深圳证券交易所《关于支持上市公司做好 2019 年年度报告审计与披露工作 的通知》的相关规定，公司已免于进行 2020 年第一季度业绩预告。 2 湖南景峰医药股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | - ...

Financial Performance - Net profit attributable to shareholders was CNY -205,977,913.47, a decrease of 513.68% year-on-year[7] - Operating revenue decreased by 32.53% to CNY 343,864,353.02 for the current period[7] - Basic earnings per share were CNY -0.2341, reflecting a decline of 513.60% compared to the same period last year[7] - The company reported a net profit attributable to shareholders of -¥142,943,425.89, a decrease of 222.48% year-on-year, driven by revenue decline and increased marketing expenses[20] - The company expects a cumulative net loss of between ¥30,000,000 and ¥20,000,000 for the year, representing a decline of 260.59% to 207.06% compared to the previous year[25] - The net profit for the current period was a loss of ¥217,135,610.65, compared to a profit of ¥31,416,855.35 in the previous period[46] - The comprehensive income total for the current period is a loss of CNY 163,341,395.87, compared to a profit of CNY 100,912,305.16 in the previous period[55] Cash Flow - The net cash flow from operating activities decreased by 80.30% to CNY 44,158,828.05 year-to-date[7] - The net cash flow from operating activities was CNY 44,158,828.05, a decrease from CNY 224,099,982.48 in the previous year[62] - Cash flow from financing activities showed a net increase of CNY 603,354,300.90, contrasting with a net outflow of CNY 89,077,227.81 in the previous year[64] - The net cash flow from financing activities was 32,398,809.45, a recovery from -170,808,332.45 in the previous period, showing improved financing conditions[68] - The total cash inflow from operating activities was 218,634.54, significantly lower than the previous period's 2,448,676.35, highlighting operational challenges[66] Assets and Liabilities - Total assets increased by 9.86% to CNY 5,742,725,808.47 compared to the end of the previous year[7] - The company's total liabilities were CNY 3,043,128,859.41, compared to CNY 2,365,035,255.69 at the end of 2018, marking an increase of around 28.6%[37] - Total current liabilities increased to CNY 1,812,213,740.36 from CNY 1,383,092,584.76, reflecting a rise of approximately 31%[37] - The company's total assets amounted to ¥5,913,529,124.37, a decrease from ¥5,957,868,700.36 in the previous period[43] - Total liabilities decreased to ¥1,096,767,866.41 from ¥1,135,594,473.33 in the previous period[43] Shareholder Information - The company reported a total of 35,089 common shareholders at the end of the reporting period[12] - The top shareholder, Ye Xiangwu, holds 19.80% of the shares, amounting to 174,166,182 shares[12] - The company did not engage in any repurchase transactions during the reporting period[14] Operational Changes - The company has initiated internal reforms to enhance the sales team's motivation and effectiveness, including hiring experienced sales management personnel[22] - The company completed a share transfer agreement, selling 11.25% of a subsidiary for ¥16.2 million, with ¥14.58 million received to date[22] Investment Activities - Investment income surged by 198,067.10% to ¥77,556,381.63, primarily due to the disposal of subsidiaries and joint ventures[20] - The company reported investment income of CNY 77,556,381.63, compared to a loss of CNY 39,176.40 in the previous period[53] Expenses - Total operating costs increased to ¥569,588,980.80, up 24.7% from ¥456,741,302.35 in the previous period[44] - The company reported a significant increase in sales expenses, which rose to ¥319,244,414.68, compared to ¥189,068,319.94 in the previous period, reflecting a 68.9% increase[44] - Research and development expenses were ¥46,617,894.92, slightly up from ¥43,842,813.79 in the previous period[44] Other Financial Metrics - The weighted average return on net assets was -8.47%, down from -5.95% in the previous year[7] - The company's cash and cash equivalents increased by 119.73% to ¥1,125,247,128.05, primarily due to the maturity of notes and increased borrowings[17] - Other receivables rose by 508.08% to ¥280,817,493.44, mainly due to increased business promotion funds and financing lease deposits[17]